Hospitals could soon publish negotiated prices

The Trump administration is reportedly considering requiring hospitals and other healthcare providers to publish the prices they charge insurance companies for services after the rates have been negotiated, The Wall Street Journal reported.

HHS has already been pushing hospitals to publish the list prices of services online, though those rules have caused some confusion for consumers. List prices often do not reflect the prices consumers or insurers actually pay. The potential new requirement would expose “for the first time the actual cost of care,” according to the WSJ.

Such a move would likely be opposed by healthcare providers and insurers, upending the traditionally opaque pricing system. HHS is asking for feedback on whether patients have a right to see the discounted prices before they receive care. The prices could end up online and give consumers more power to make decisions about their healthcare services, as well as introduce more competition that could end up lowering healthcare costs overall.

Healthcare prices vary widely across the country and by setting, and often patients have no idea how much services cost until after they receive care.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.